To cite this paper use one of the standards below:
Recently, many studies described tyrosine kinases as essential mediators of the signalling cascade, with significative roles in many biological processes, including the pathophysiology of cancer. The imatinib was the first inhibitor of Bcr-Abl tyrosine kinase (TKI) for the treatment of Chronic Myeloid Leukemia (CML) that showed activity against some cells of human lung cancer. Thus, the objective of this work is the synthesis and the antimyeloproliferative evaluation of ten new imatinib analogues. These compounds were designed from molecular hybridization between isatins and derivatives, used as TKI, with the phenylamino pyrimidine (PAP) skeleton, the significant pharmacophoric fragment of imatinib. The final products 1-2 (a-e) were synthesized with a high degree of purity and in moderate yields and were evaluated against K562 (CML cells) and A549 (lung cancer cells) lines. The results have shown that the derivatives were inactive in K562, but presented good activity for A549, being more active than imatinib.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper